Early treatment with CsA decreased ifn-β1, cxcl14 and mt1-mmp expression (p<0.05) in tumor CD11b+ cells compared to controls, and delayed CsA administration decreased arg-1 and cxcl14 expression. This evidence concerns the gene ITGAM and neoplasm.